Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739813 | 0.93 | NAAA (0.46) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL7739816 | 0.93 | NAAA (0.46) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL9830399 | 0.92 | PRMT1 (0.59) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL24982662 | 0.87 | NAAA (0.51) | NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL9831902 | 0.85 | NAAA (0.60) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL9830181 | 0.85 | NAAA (0.65) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL2331473 | 0.84 | EPHX2 (0.51) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL5655426 | 0.83 | NAAA (0.68) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL7897834 | 0.83 | NAAA (0.68) | ADRA1ANAAAPRMT1GNAI3GNAO1 | |
| SCHEMBL9831292 | 0.83 | NAAA (0.62) | ADRA1ANAAAPRMT1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-9370492-B2 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370492-B2 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2007093226-A1 | ORAL IBANDRONATE FORMULATIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| EP-1792624-A1 | Modified amino acids and compositions comprising them for delivering active agents | Emisphere Technologies, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | SLC1A5, SLC7A5, SLC7A1 | ADRA1A 2222/4885NAAA 3916/4885PRMT1 3456/4885 |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | SLC1A5, SLC7A5, SLC7A1 | ADRA1A 2203/4885NAAA 3924/4885PRMT1 3459/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | ADRA1A 4101/4885NAAA 3559/4885PRMT1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.